AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL

AstraZeneca AND ELI LILLY AND COMPANY Announce Continuation of Pivotal Clinical
Trial for People with Early Alzheimer's Disease

Phase II/III trial of AZD3293, an oral potent small molecule BACE inhibitor,

will continue to Phase III after positive interim safety data

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase
II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor
currently in development as a potential treatment for early Alzheimer's disease,
will continue into Phase III of the Phase II/III seamless trial.

The AMARANTH independent data monitoring committee recommended the study
continue without modification after a scheduled interim safety analysis was
conducted. The analysis was not designed to review efficacy.

Menelas Pangalos, Executive Vice President, IMED Biotech Unit, AstraZeneca,
said: "Alzheimer's disease remains one of the biggest challenges facing medical
science today. BACE inhibitors have the potential to target one of the key
drivers of disease progression and we are delighted that our combined efforts
have resulted in the development of AZD3293 moving into the next phase of study.
Disease modifying approaches, such as this, have the potential to transform the
treatment of Alzheimer's disease and help patients in this area of large unmet
medical need."

AZD3293 has been shown in Phase I studies to reduce levels of amyloid beta in
the cerebro-spinal fluid of people with Alzheimer's disease and healthy
volunteers. The progression of Alzheimer's disease is characterised by the
accumulation of amyloid plaque in the brain. BACE is an enzyme associated with
the development of amyloid beta. Inhibiting BACE is expected to prevent the
formation of amyloid plaque and eventually slow the progression of the disease.

Phyllis Ferrell, vice president and global development leader for Alzheimer's
disease at Lilly said: "This is an important and meaningful step forward on the
path to better understand the Alzheimer's puzzle. We'd like to thank the
AMARANTH participants and the trial investigators for taking part in this
important study and thank our colleagues at AstraZeneca for their partnership."

AstraZeneca and Lilly have also announced the planned initiation of a new Phase
III trial for AZD3293. The trial, named DAYBREAK, will study the safety and
efficacy of AZD3293 in people with mild Alzheimer's dementia. DAYBREAK will
begin enrolling participants in the third quarter of 2016.

AstraZeneca and Lilly announced an alliance in
2014 (https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca
-lilly-bace-inhibitor-azd3293-alzheimers-disease-16092014.html) for the
development and commercialisation of AZD3293/LY3314814. Under the agreement,
Lilly leads clinical development, working with researchers from AstraZeneca's
Neuroscience Research and Development Team, while AstraZeneca will be
responsible for manufacturing. The companies will take joint responsibility for
commercialisation of the molecule and will share all future costs equally for
development and commercialisation, as well as net global revenues post-launch.

Financial Considerations

Under the terms of the agreement, AstraZeneca will receive a further milestone
payment from Lilly now that AZD3293 will move into Phase III testing. The
payment of $100 million will be reported as Externalisation Revenue in
AstraZeneca's financial statements and does not change the financial guidance
for 2016.

About the AMARANTH study

AMARANTH is a Phase II/III study that is investigating the safety and efficacy
of AZD3293 and testing the hypothesis that it is a disease-modifying treatment
for patients with early Alzheimer's disease. Early Alzheimer's disease is
defined as the continuum of patients with mild cognitive impairment (MCI) due to
Alzheimer's disease and patients diagnosed with mild Alzheimer's dementia. The
study, which has a two-year treatment period, aims to enroll more than 2200
patients in 14 countries.

About Alzheimer's disease

Alzheimer's disease, a fatal illness, is the most common form of dementia,
accounting for 60 to 80 percent of dementia cases. There are currently an
estimated 46 million people living with dementia worldwide, and this number is
expected to grow to more than 74 million in 2030 and 131 million in 2050. Only
50 percent of people with dementia ever receive a formal diagnosis, and
Alzheimer's disease continues to be one of the most significant health
challenges facing the world. The total estimated worldwide cost of dementia in
2015 was $818 billion. By 2018, dementia will become a trillion dollar disease,
rising to $2 trillion by 2030.



About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and newsroom.lilly.com/social-channels.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas -
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology - as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Neil Burrows         UK/Global            +44 20 7604 8032
Vanessa Rhodes       UK/Global            +44 20 7604 8037
Karen Birmingham     UK/Global            +44 20 7604 8120
Jacob Lund           Sweden               +46 8 553 260 20
Michele Meixell      US                   +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen                       +44 7818 524185
Eugenia Litz         RIA                  +44 7884 735627
Nick Stone           CVMD                 +44 7717 618834
Craig Marks          Finance              +44 7881 615764
Christer Gruvris     Consensus Forecasts  +44 7827 836825
US
Lindsey Trickett       Oncology, ING      +1 240 543 7970
Mitch Chan             Oncology           +1 240 477 3771
Dial / Toll-Free                           +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and
Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

08 April 2016

-ENDS-